Content
12/18/2024
New Haven, CT USA
Veradermics
completed $75 million Series B Round funding. Investors include
Suvretta Capital Management (lead), Connecticut Innovations, J.W. Childs Associates, Longitude Capital, Osage University Partners, PhiFund Ventures, Surveyor Capital.
About
Veradermics is a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class treatments for common dermatologic conditions. The company's lead candidate, VDPHL01, is a non-hormonal oral therapeutic that is currently being evaluated for the treatment of AGA/PHL in both men and women. Additional pipeline programs address common dermatologic conditions including common warts and molluscum contagiosum.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
